

# Frequency of non-alcoholic fatty liver disease in a series of forensic cases in Mexico

Frecuencia de hígado graso no alcohólico en una serie de casos forenses en México

Rafael Rojano-Ramón<sup>1</sup>, Ana Laura Calderón-Garcidueñas<sup>2</sup>,  
Rubén Ruiz-Ramos<sup>3</sup>, Noé López-Amador<sup>4</sup>

DOI: 10.19136/hs.a20n2.3839

Original Article

Received date: June 4, 2020

Accepted date: January 6, 2021

Corresponding author:

Ana Laura Calderón-Garcidueñas. Address: School of Medicine, Universidad Veracruzana,  
Calle Agustín de Iturbide S/N, Zona Centro, 91700 Veracruz, México.  
Email: acald911@hotmail.com

## Abstract

**Objective:** To determine the frequency of non-alcoholic fatty liver in individuals with not known history of liver disease, who died instantly in a traffic accident.

**Materials and Methods:** It was a prospective and cross-sectional study of a series of autopsy cases, with a convenience sample obtained from the forensic medical service in the municipality of Boca del Río, Mexico, during the period from January to December 2016. The variables studied included age, sex, weight, height, abdominal circumference, thickness of the adipose panicle, cause of death and findings of liver biopsy.

**Results:** A 78.1% of the 32 cases studied were men. The average age was 48 years old (range 20-80 years old). The body mass index range was 17-33. 34% of the cases had fatty liver. 27.3% of cases with fatty liver had a normal body mass index.

**Conclusions:** This postmortem study showed a higher frequency of asymptomatic hepatic steatosis than previously reported in the Mexican population. It is necessary to establish timely national measures to detect and to prevent complications of this disease.

**Key words:** Non-alcoholic fatty liver disease; obesity; autopsy.

## Resumen

**Objetivo:** Determinar la frecuencia de hígado graso no alcohólico en individuos sin antecedentes conocidos de enfermedad hepática, que murieron instantáneamente en un accidente de tráfico.

**Materiales y Métodos:** Fue un estudio prospectivo y transversal, de una serie de casos de autopsia, con una muestra por conveniencia obtenida en el servicio médico forense en el municipio de Boca del Río, México, durante el período de enero a diciembre de 2016. Las variables estudiadas incluyeron edad, sexo, peso, altura, perímetro abdominal, grosor del pániculo adiposo, causa de muerte y hallazgos de la biopsia hepática.

**Resultados:** De los 32 casos estudiados, el 78,1% eran hombres. La edad promedio fue de 48 años (rango 20-80 años). El rango del índice de masa corporal fue de 17-33. Un 34% de los casos tenían hígado graso. El 27.3% de los casos con hígado graso tenían un índice de masa corporal normal.

**Conclusiones:** Este estudio postmortem mostró una frecuencia más alta de esteatosis hepática asintomática que la reportada previamente en la población mexicana. Es necesario establecer medidas nacionales oportunas para detectar y prevenir complicaciones de esta enfermedad.

**Palabras clave:** Esteatosis hepática no alcohólica; obesidad; autopsia; mexicanos.

<sup>1</sup>Physician, Master in Forensic Science. Instituto de Medicina Forense, Universidad Veracruzana, México.

<sup>2</sup>Physician, Doctor (PhD) in Science, Instituto de Medicina Forense, Universidad Veracruzana, México.

<sup>3</sup>Biologist, Doctor (PhD) in Science, School of Medicine, Universidad Veracruzana, México.

<sup>4</sup>Physician, Master in Forensic Science Instituto de Medicina Forense, Universidad Veracruzana, México.

## Introduction

Obesity has become a worldwide epidemic and it has nearly tripled since 1975. According to data from the World Health Organization (WHO), in 2016, more than 1.9 billion adults, 18 year old and older, were overweight. Over 650 million of these were obese<sup>1</sup>. Obesity and overweight together according to the National Institutes of Health are the second leading cause of preventable death in the United States<sup>2</sup>.

Obesity prevalence has increased progressively since the 1980s in Mexico. Obesity affects actually over 30% of the adult population<sup>3</sup>. By 2050, more people will be obese than overweight and there will be 12 million cumulative incidence cases of diabetes and 8 million cumulative incidence cases of heart disease<sup>3</sup>. In this country, there is a global average of 38% overweight (defined as body mass index (BMI) > 25 kg / m<sup>2</sup>), and 21 % obesity (BMI > 30 kg / m<sup>2</sup>). The prevalence of overweight is higher in men (41.1 %) than in women (35.6%), while the prevalence of obesity is inverse, higher in women (21.5%) than in men (14.9%)<sup>4</sup>.

On the other hand, chronic liver disease has several etiologies. The main etiology worldwide is chronic alcohol abuse, followed by viral hepatitis and nonalcoholic fatty liver disease (NAFLD)<sup>5</sup>. NAFLD includes simple steatosis, non-alcoholic steatohepatitis (NASH) and NAFLD induced cirrhosis. The epidemiology of NAFLD is usually parallel to the prevalence of obesity, but a percentage of patients have normal body mass index (BMI)<sup>6</sup>. In Korea, the prevalence of <NAFLD< increased from 18.6% in 1998-2001 to 21.5% in 2016-2017 (almost 3%)<sup>7</sup>. NAFLD increased from 20.0% (1988-1994) to 31.9% (2013-2016) (almost 12%)<sup>8</sup> in USA. In general terms, NAFLD affects 25.24% of the world population<sup>9</sup>.

NAFLD is characterized by an accumulation of lipids in the form of triglycerides (steatosis) in the liver parenchyma ( $\geq 5\%$ ), in the absence of excessive alcohol intake (< 20 g / day) or other chronic liver diseases and it is considered as expression in the liver of the metabolic syndrome<sup>9</sup>. The diagnosis of NASH requires the exclusion of other liver diseases, such as alcoholic liver disease, viral hepatitis and Wilson disease<sup>6</sup>. The exact prevalence of NASH in the general population is unknown.

A study in young individuals with overweight or obesity (37.1 years old,  $\pm 13.5$ ) performed in Mexico showed that 57% (290/505) of the studied population was at risk for nonalcoholic steatohepatitis<sup>10</sup>. Non-alcoholic hepatic steatosis is the most frequent cause of chronic alterations in liver function tests in asymptomatic individuals<sup>10</sup>.

Some models predict that if the epidemic of obesity and diabetes mellitus continues like now, NAFLD and NASH prevalence will increase, especially NASH, with a calculated increase of 15-56%<sup>11</sup>.

Therefore, the objective of this postmortem study was to determine the frequency of hepatic steatosis/hepatitis in a case series of apparently asymptomatic individuals who died suddenly due to traffic accidents without previous report of liver disease. The study of this sample could provide a clearer idea of the frequency of liver morphological changes in asymptomatic subjects.

## Materials and Methods

The protocol was reviewed and approved by the responsible Institution.

Autopsies were performed at the Coroner's Office, Municipality of Boca del Río, Veracruz, Mexico, during January to December 2016. It was a convenience sample that ultimately included 32 forensic cases.

**Inclusion criteria.** The corpses of individuals, 16-year-old and older, with eight or less hours since declared death in a traffic accident, were included.

**Exclusion criteria.** Excluded cases were those with macroscopic liver damage, a known background of viral or chronic liver disease, alcoholism, and positive toxicological tests for alcohol and/ or drugs of abuse.

The variables studied included age, sex, weight, height, abdominal perimeter, fat panicle thickness and direct cause of death. The thickness of the adipose panicle was measured *in situ* at the level of the lower border of the umbilical scar, once the longitudinal incision for the autopsy had been made.

After measuring and weighing the liver, two 1x1x1 cm, wedge biopsies were performed wedge biopsies corresponding to the lateral segment of left lobe and posterior segment of right lobe; subsequently, they were fixed with 4% buffered formalin for 24 hours. Hematoxylin & eosin and Masson's trichrome stains were performed, and biopsies were analyzed with a light microscope by a certified pathologist according to the NASH CRN Scoring System table 1; with this score system, a NAS score of  $\geq 5$  correlates with a diagnosis of "definite NASH" whereas  $\text{NAS} \leq 3$  correlates with a diagnosis of "not NASH"<sup>12</sup>.

**Ethical considerations:** This study does not include personal data. Forensic autopsies do not require authorization from family members and they are carried out at the request of the State, represented by the prosecuting attorney according

**Table 1.** NASH CRN Scoring System: NAS and Fibrosis Score

Steatosis Grade		Lobular Inflammation		Hepatocellular Ballooning		Fibrosis Score	
D*	(%)	D	F**	D	F	D	F
0	<5%	0	None	0	None	0	None
1	5-33	1	<2 foci/20x optical field	1	Mild, few	1a	Mild (delicate) zone 3 perisinusoidal fibrosis
						1b	Moderate (dense) zone 3 perisinusoidal fibrosis
2	33-66	2	2-4 foci/20x optical field	2	Moderated/ marked, many	1c	Portal/periportal fibrosis only
						2	Zone 3 perisinusoidal fibrosis with portal/ periportal fibrosis
3	>66	3	>4 foci/20x optical field			3	Bridging fibrosis
						4	Cirrhosis

Source: According to Puri and Sanyal<sup>12</sup> D\*: Degree F\*\*: Findings  
NAS: Nonalcoholic fatty liver disease activity score

to the Code of Criminal Procedures and the General Law of Health; however, the protocol was registered at the General Attorney, which approved the study and sampling.

## Results

During the period from May 4, 2016 to November 15, 2016, 32 cases that met the inclusion criteria previously discussed were documented and collected. All deaths were instantaneous. The toxicological test ruled out recent drugs or alcohol intake.

78.1% of the 32 cases studied, (n=25) were males and 21.8% (n=7) were females. The average age was 48 years old with a range of 20-80 years old table 2.

The body mass index (BMI) range was 17-33; no grade II-IV obesity was observed. The abdominal perimeter ranged between 60-95 cm.

The thickness range of the adipose panicle was 1-7 cm, with the following distribution according to weight: normal weight, 1-4 cm (mode=2); overweight, 3-7 cm (mode= 6), and grade I obesity, 5-7 cm (mode= 5).The weight of the liver had a range of 1300 to 1850 g table 3.

The study of cases with low or normal BMI, without steatosis, showed that of 14 cases with normal histology, one (7.1%) was a woman with low IBM and 13 (92.9%) had normal IBM. Two of these were women and 11 were men. The women in this group had a liver weight of 1300 and 1500 g, with an average of 1416 g. In the group of men, the range was between 1100-1700 g with an average of 1531 g.

Finding in cases with overweight / obesity, without steatosis, were as follows: There were seven cases, 71.4% (n=5) men and 28.6 % (n=2) woman. The liver weight range in men was 1575-1850 g, while the overweight woman had a liver of 1700 g. There was also a woman with grade I obesity (liver, 1650 g).

**Table 2.** Age, sex, BMI and abdominal perimeter.

A*	S	Weights and measures			BMI	Liver biopsy (NASH-CRN Classification)	
		Liver (g)	Waist (cm)	AP (cm)		ST grade	Lobular I
37	F	1500	72	3	23.3 NL	0	0
75	F	1650	95	5	33.0 O-I	0	0
65	M	1450	82	2	23.8 NL	0	0
25	M	1740	80	3	27.0 OW	0	0
23	M	1450	78	4	20.55 NL	0	0
36	F	1700	90	6	25.9 OW	0	0
58	M	1100	64	1	24.98 NL	0	0
55	M	1750	89	3	27.68 OW	1	0
35	M	1700	72	2	23.66 NL	0	0
38	M	1450	80	5	31.89 O-I	2	1
29	M	1500	65	3	25.71 OW	3	1
48	M	1600	78	5	25.95 OW	1	0
32	M	1450	68	4	22.23 NL	0	0
84	M	1650	72	3	23.03 NL	0	0
67	M	1700	87	6	28.34 OW	0	0
71	M	1450	72	2	19.84 NL	0	0
47	M	1850	84	7	29.07 OW	0	0
72	M	1650	70	2	19.84 NL	0	0
40	F	1450	60	4	19.81 NL	0	0
20	F	1300	60	2	17.36 LW	0	0
33	M	1650	86	4	27.36 OW	0	0
67	M	1575	89	4	25.06 OW	0	0
65	M	1650	70	2	22.31 NL	0	0
44	M	1750	72	2	23.53 NL	1	0
35	M	1780	92	6	28.09 OW	1	0
85	M	1650	80	6	27.44 OW	1	0
62	M	1700	69	2	22.49 NL	0	0
46	F	1600	79	7	31.25 O-I	3	1
28	M	1600	80	3	23.39 NL	0	0
56	M	1450	78	3	24.00 NL	1	0
25	F	1450	71	7	24.09 NL	3	1
31	M	1750	89	6	29.07 OW	1	0

Source: Own data

**Table 3.** Findings from liver biopsy, weights and measures.

A*	S	Weights and measures			BMI	Liver biopsy (NASHCRN Classification)	
		Liver (g)	Waist (cm)	AP (cm)		ST grade	Lobular I
37	F	1500	72	3	23.3 NL	0	0
75	F	1650	95	5	33.0 O-I	0	0
65	M	1450	82	2	23.8 NL	0	0
25	M	1740	80	3	27.0 OW	0	0
23	M	1450	78	4	20.55 NL	0	0
36	F	1700	90	6	25.9 OW	0	0
58	M	1100	64	1	24.98 NL	0	0
55	M	1750	89	3	27.68 OW	1	0
35	M	1700	72	2	23.66 NL	0	0
38	M	1450	80	5	31.89 O-I	2	1
29	M	1500	65	3	25.71 OW	3	1
48	M	1600	78	5	25.95 OW	1	0
32	M	1450	68	4	22.23 NL	0	0
84	M	1650	72	3	23.03 NL	0	0
67	M	1700	87	6	28.34 OW	0	0
71	M	1450	72	2	19.84 NL	0	0
47	M	1850	84	7	29.07 OW	0	0
72	M	1650	70	2	19.84 NL	0	0
40	F	1450	60	4	19.81 NL	0	0
20	F	1300	60	2	17.36 LW	0	0
33	M	1650	86	4	27.36 OW	0	0
67	M	1575	89	4	25.06 OW	0	0
65	M	1650	70	2	22.31 NL	0	0
44	M	1750	72	2	23.53 NL	1	0
35	M	1780	92	6	28.09 OW	1	0
85	M	1650	80	6	27.44 OW	1	0
62	M	1700	69	2	22.49 NL	0	0
46	F	1600	79	7	31.25 O-I	3	1
28	M	1600	80	3	23.39 NL	0	0
56	M	1450	78	3	24.00 NL	1	0
25	F	1450	71	7	24.09 NL	3	1
31	M	1750	89	6	29.07 OW	1	0

Source: Own data

A: Age; Sx: Sex; AP: adipose panicle; ST: Steatosis; I: Inflammation. BMI (body mass index); NL: normal; OW: overweight; OB-I: Obesity grade I.


In liver biopsies, fibrosis and ballooning degeneration of hepatocytes were not documented, and steatosis grades 1-3, was observed figure 1. Of the 32 cases studied, 34% (n=11) presented steatosis table 3. The distribution of steatosis by grade was as follows: grade I, 7 cases; grade 2, 1 case, and grade 3, 3 cases. In 12.5% (n=4), mild inflammation was observed that coincided with the three cases of grade 3-steatosis, and the case of grade 2-steatosis. With a maximum score of 4, the steatohepatitis activity in this sample was “indeterminate”.

## Discussion

Non-alcoholic fatty liver disease (NAFLD) is a complex entity characterized by steatosis, and it can progress to nonalcoholic steatohepatitis (NASH), fibrosis, and ultimately hepatocellular carcinoma<sup>13,14</sup>.

NAFLD is associated with obesity and metabolic syndrome. Hepatic steatosis is related to body adiposity, especially central obesity<sup>15</sup>. However, in this study, central obesity was found only in a 36-years-old, over-weight women with 90 cm of abdominal circumference and in 75-years-old women with obesity grade I, and abdominal circumference of 95 cm. Neither one had hepatic steatosis.

Figure 1. Liver biopsy. Woman, 25 years old with normal BMI, liver weight of 1450 g and steatosis grade 3 with mild inflammation (arrow) (H&E, A, 100 X and B, 400 X).



Source: Own data

In the other hand, the thickness of the adipose panicle appeared to be related to the increase in body weight, in such a way that no corpses of subject with normal IBM had more than 4 cm of adipose panicle. In overweight and obesity grade I subjects, the maximum thickness was 7 cm. There is a relationship between obesity as cause of death and increased thickness of adipose panicle for values between 8.5 and 9.5 cm<sup>16</sup>.

The liver is about 2% of the weight of an adult<sup>17</sup>. Livers in this study weighed between 1.6 and 2.9% of body weight. The corps with livers corresponding to 2.7-2.9% of body weight, had normal or low body weight. Therefore, it is feasible to observe even grade 3-steatosis in subjects with a normal BMI and an adequate liver weight. In fact, in some forensic studies, liver steatosis has been detected in 15% of non-obese subjects, in 65% of obese ones and in 85% of those with morbid obesity<sup>18</sup>.

According to NAFLD Activity Score<sup>12,19</sup>, a score of  $\geq 5$  NASH is required to diagnose steatohepatitis. In this sample, steatosis was very frequent (34.4%). However, although in 12.5%, mild inflammation was observed, the score was not enough to diagnose hepatitis. If we realize that these individuals were clinically asymptomatic and were mostly only overweight, the findings are worrisome. All the cases with liver inflammation had steatosis and one subject had normal weight, one was overweight and two had obesity grade I. However, although in 12.5%, mild inflammation was observed, the score was not enough to diagnose hepatitis in these cases. Therefore, having a patient with a normal body mass index does not rule out the possibility of having a fatty liver disease.

There is a wide variability for the development of fatty liver, favored among other things, by genetic polymorphisms combined with other factors such as excess intake of calories, high-fructose syrup beverage consumption and lack of exercise<sup>20</sup>.

These polymorphisms include the I148M *PNPLA3* variant<sup>21</sup> as well as the *TM6SF2*, *MBOAT7* and *GCKR* genes<sup>21,22</sup>. The isoleucine to methionine substitution at position 148 in the patatin-like phospholipase domain containing 3-protein (*PNPLA3* gene; I148M variant) is associated with steatosis and an increased risk of chronic liver disease ranging from hepatitis to hepatocellular carcinoma<sup>21</sup>. Carriers of the *PNPLA3* gene variant develop an excess of adiposity in childhood and are at higher risk of developing fatty liver<sup>23</sup>.

Genetic variant *TM6SF2* E167K induces increased hepatocyte fat content by reducing circulating apolipoprotein B100 levels<sup>22</sup>. Also, rs641738 C>T variant in the locus that contains the membrane bound O-acyltransferase domain-containing 7 gene (*MBOAT7*, also called *LPIAT1*) is associated with lower protein expression in the liver and changes in plasma phosphatidylinositol species<sup>24</sup>. It seems to be an association between the *MBOAT7* rs641738 gene variant and the development and severity of NAFLD in individuals of European descent<sup>24</sup>.

A Mexican study reported that *PNPLA3*, *LYPLALI*, *GCKR* and *PPP1R3B* polymorphisms were associated with higher triglyceride content in the liver<sup>25</sup>. The study of these variants in subjects with steatosis would highlight those individuals with a higher risk of evolving to steatohepatitis.

Most studies of the prevalence of NAFLD have been performed using ultrasonography (US), computed tomography or magnetic resonance spectroscopy methods<sup>26</sup>. In spite of recent advances, histology remains the gold standard for diagnosis of NAFLD; therefore, this postmortem study provided valuable material of asymptomatic subjects, impossible to obtain by other means.

The prevalence of NAFLD in the general population is very variable. It affects 30% of the United States of America population<sup>27</sup>. In Iran, NAFLD prevalence in 116 cases of young cadaveric organ donors was 13% and 80% had mild hepatic steatosis<sup>28</sup>.

In 2006, two different US studies in asymptomatic Mexican population showed a NAFLD prevalence of 15.7-17%<sup>29,30</sup>. Although, this postmortem preliminary study is limited by the size of the sample, the lack of genetic polymorphisms analysis and of liver functional tests, it found that the percentage of asymptomatic subjects affected by steatosis is higher than that reported in previous studies in Mexican population<sup>29,30</sup>. Furthermore, 27.3% of the cases with NAFLD had a normal

BMI. Public policies based on population education and the abolition of junk food production are required. A reduction in both, high-fructose syrup beverage production and consumption in individuals of all ages should be sought<sup>31</sup>. It has been proven in animal models that, these beverages are metabolized to glyceraldehyde (GA) in the liver and GA-derived advanced glycation end-products are generated and may induce the onset/progression of non-alcoholic fatty liver disease<sup>31</sup>. In the same way the increase in physical activity and the promotion of healthy and balanced food should be part of public health policies. Returning to the milpa diet<sup>32</sup> - the healthy eating model of Mesoamerican origin, which has milpa products (corn, beans, chili and squash) as its nutritional center is a nutritionally balanced option and bring drinking water to all communities must be part of the strategies to combat this growing pathology.

## Conclusions

The 34 % of subjects without symptoms of liver disease, who died in traffic accidents, had hepatic steatosis. This suggests that the problem of silent steatosis in Mexico, is greater than previously thought and requires the establishment of national timely measures to prevent it and to detect early complications.

## Acknowledgment

To the National Council of Science and Technology (CONACYT) for the master's scholarship awarded to RRR.

To the General Attorney of Veracruz state (Fiscalía General del Estado de Veracruz) for the facilities provided to carry out this work

## Conflict of interest.

There is no conflict of interest between authors.

## References

1. World Health Organization. Obesity and overweight. [Cited 9 Jan 2020.] Available from URL: <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight>

2. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment, of overweight and obesity in adults. NIH Publications, 1998; 98: 4083, [Cited 9 Jan 2020.] Available from URL: <https://books.google.com.mx/books?hl=es&lr=&id=3XVrAAAAMAAJ&oi=fnd&pg=PR7&dq=Clinical+guidelines+on+the+identification,+evaluation,+and+treatment+of+overweight+and+obesity+in+adults&ots=nPWVCERK8O&sig=NSVhM5tZq2VaYiOCt3WFfRTrDu0#v=onepage&q=Clinical%20guidelines%20on%20the%20identification%2C%20evaluation%2C%20and%20treatment%20of%20overweight%20and%20obesity%20in%20adults&f=false>
3. Rtveladze K, Marsh T, Barquera S, Sánchez- Romero LM, Levy D, Meléndez G, Webber L, Kilpi F, McPherson K, Brown M. Obesity prevalence in Mexico: impact on health and economic burden. *Public Health Nutr.* 2014;17(1):233–239. doi:10.1017/S1368980013000086.
4. Lizardi-Cervera J, Becerra LI, Chávez-Tapia NC, Ramos OME, Uribe EM. Prevalencia de hígado graso no alcohólico y síndrome metabólico en población asintomática. *Rev Gastroenterol Mex* 2006; 71 (4): 453-459.
5. Mokdad AA, Lopez AD, Shahraz S, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. *BMC Med.* 2014; 12: 145. doi: 10.1186/s12916-014-0145-y
6. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. *Nat Rev Gastroenterol Hepatol.* 2018; 15(1):11–20. doi: 10.1038/nrgastro.2017.109
7. Park SH, Plank LD, Suk KT, Park YE, Lee J, Choi JH, Heo NY, Park J, Kim TO, Moon YS, Kim HK, Jang HJ, Park HY, Kim DJ. Trends in the prevalence of chronic liver disease in the Korean adult population, 1998-2017. *Clin Mol Hepatol.* 2020; 26(2):209-215. DOI: 10.3350/cmh.2019.0065
8. Younossi ZM, Stepanova M, Younossi Y, Golabi P, Mishra A, Rafiq N, Henry L. Epidemiology of chronic liver diseases in the USA in the past three decades. *Gut* 2020; 69:564-568. DOI: 10.1136/gutjnl-2019-318813.
9. McAvoy NFJ, Campbell JW, Hayes P. Non-alcoholic fatty liver disease: natural history, pathogenesis and treatment. *The British J of Diabetes & Vascular Disease* 2006; 6: 251-260. DOI: 10.1177/14746514060060060201
10. Sepulveda-Villegas M, Roman S, Rivera-Iñiguez I, Ojeda-Granados C, Gonzalez-Aldaco K, Torres-Reyes LA, et al. High prevalence of nonalcoholic steatohepatitis and abnormal liver stiffness in a young and obese Mexican population. *PLoS ONE* 2019; 14(1): e0208926. DOI: 10.1371/journal.pone.0208926
11. Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. *J. Hepatol* 2018; 69 (4):896–904. DOI: <https://doi.org/10.1016/j.jhep.2018.05.036>
12. Puri P, Sanyal AJ. Nonalcoholic fatty liver disease: Definitions, risk factors and workup. *Clin Liver Dis (Hoboken).* 2012; 1(4): 99-103. DOI: 10.1002/cld.81
13. Hardy T, Oakley F, Anstee QM, Day CP. Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum. *Annu Rev Pathol.* 2016; 11: 451-96. DOI: 10.1146/annurev-pathol-012615-044224.
14. Vallet-Pichard A, Parlati L, Pol S. Epidemiology of non-alcoholic steatohepatitis. extent/ burden of the problem and its impact on public health. *Presse Med.* 2019; 1459-1467. DOI: 10.1016/j.lpm.2019.08.008.
15. Thomas EL, Hamilton G, Patel N, O'Dwyer R, Doré CJ, R D Goldin RD, J D Bell JD, Taylor-Robinson SD. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. *Gut* 2005; 54: 122-127. DOI: 10.1136/gut.2003.036566.
16. Gonçalves LB, Miot HA, Domingues MAC, et al. Autopsy Patients With Obesity or Metabolic Syndrome as Basic Cause of Death: Are There Pathological Differences Between These Groups? *Clin Med Insights Pathol.* 2018;11:1-7. DOI: 10.1177/1179555718791575.
17. Sibulesky L. Normal liver anatomy. *Clinical Liver Disease* 2013; 2 (Suppl) (S1-S3) DOI: 10.1002/cld.124
18. Verdelho-Machado M, Cortéz-Pinto H. Fatty liver in lean patients: is it a different disease? *Annals of Gastroenterology* 2012; 25 (1): 1-2.
19. Arab JP, Schalper KA, Arrese M. Clasificación histológica para hígado graso no alcohólico: NAFLD activity score (NAS). *Gastroenterol Latinoam* 2014; 25 (4): 308-313.

20. Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: Clinical impact. *J Hepatol.* 2018; 68 (2): 268-279. DOI: 10.1016/j.jhep.2017.09.003.
21. Maglio C, Pirazzia C, Pujia A, Pujia A, Valenti L, Romeo S. The PNPLA3 I148M variant and chronic liver disease: When a genetic mutation meets nutrients. *Food Research International* 2014; 63, Part B: 239-243. <https://doi.org/10.1016/j.foodres.2014.01.055>
22. Prill, S., Caddeo, A., Baselli, G, Jamialahmadi O, Dongiovanni P, Rametta R, Kanebratt KP, Pujia A, Pingitore P, Mancina RM, Lindén D, Whatling C, Janefeldt A, Kozyra M, Ingelman-Sundberg M, Valenti L, Andersson TB, Stefano Romeo S. The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids. *Sci Rep* 2019; 9 (1): 11585. DOI:10.1038/s41598-019-47737-w
23. Lin YC, Chang P, Hu FC, Yang WS, Chang MS, Ni YH. A common variant in the PNPLA3 gene is a risk factor for non-alcoholic fatty liver disease in obese Taiwanese children. *J Pediatrics* 2011; 158 (5): 740-744. DOI: 10.1016/j.jpeds.2010.11.016
24. Mancina RM, Dongiovanni P, Petta S, Pingitore P, Meroni M, Rametta R et al. The MBOAT7-TMC4 Variant rs641738 increases risk of nonalcoholic fatty liver disease in Individuals of European descent. *Gastroenterology.* 2016;150(5):1219-1230.e6. DOI: 10.1053/j.gastro.2016.01.032.
25. León-Mimila P, Vega-Badillo J, Gutiérrez-Vidal R, et al. A genetic risk score is associated with hepatic triglyceride content and non-alcoholic steatohepatitis in Mexicans with morbid obesity. *Exp Mol Pathol.* 2015; 98(2): 178-83. DOI:10.1016/j.yexmp.2015.01.012.
26. Qian LL, Wu L, Zhang L, et al. Serum biomarkers combined with ultrasonography for early diagnosis of non-alcoholic fatty liver disease confirmed by magnetic resonance spectroscopy. *Acta Pharmacol Sin.* 2019; DOI: 10.1038
27. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. *JAMA* 2015; 313: 2263-2273. DOI: 10.1001/jama.2015.5370.
28. Jafarian A, Ebrahimi A, Ardalan FA, Dashti H, Rahimi M, Salehi M, Tossi MN. NAFLD Prevalence in a Young Cadaveric Organ Donor Population. *Hepat Mon.* 2014; 14(10): e21574. DOI: 10.5812/hepatmon.21574
29. Roesch-Dietlen F, Dorantes-Cuéllar A, Carrillo-Toledo MG, Martínez-Sibaja C, Rojas-Carrera S, Bonilla-Rojas S, Uchino-Higueras V, Lagunas L, Carrasco-Arróniz MA, Soler-Leal B, León-Valdivieso J, Cid-Juárez S, Martínez JA. Frecuencia del hígado graso no alcohólico en un grupo de pacientes con síndrome metabólico estudiado en la Ciudad de Veracruz. *Rev Gastroenterol Mex.* 2006; 71(4): 446-452. <https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=14139>
30. Lizardi-Cervera J, Becerra-Laparra I, Chávez-Tapia NC, Ramos-Ostos ME, Uribe M. Prevalence of NAFLD and metabolic syndrome in asymptomatic subjects. *Rev Gastroenterol Mex.* 2006; 71(4): 453-9.
31. Takata T, Sakasai-Sakai A, Takino JI, et al. Evidence for Toxic Advanced Glycation End-Products Generated in the Normal Rat Liver. *Nutrients.* 2019;11(7). DOI:10.3390/nu11071612.
32. Almaguer-González JA, García-Ramírez HJ, Vargas-Vite V, Padilla-Mirazo M. La dieta de la Milpa: Modelo de alimentación Mesoamericana saludable y culturalmente pertinente. Secretaría de Salud. México 2018.